Pulmonary Inflammation Articles & Analysis: Older
3 news found
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
Athenson continued, “We are now much closer to improving the lives of 1.2M patients battling severe COPD and ILD (pulmonary fibrosis) and who struggle with each breath to perform the day-to-day activities that most people take for granted. ...
The FDA has approved a clinical trial with AVM0703 in severe ARDS based on its rapid monocyte and neutrophil reduction which could alleviate the pulmonary inflammation so problematic for ARDS patients, and its NKT mobilization. ...